ZENTALIS PHARMACEUTICALS INC (ZNTL)

US98943L1070 - Common Stock

11.71  +0.6 (+5.4%)

After market: 11.71 0 (0%)

Fundamental Rating

2

ZNTL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of ZNTL is average, but there are quite some concerns on its profitability. ZNTL is valued expensive and it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZNTL has reported negative net income.
ZNTL had a negative operating cash flow in the past year.
In the past 5 years ZNTL always reported negative net income.
ZNTL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ZNTL has a Return On Assets of -52.96%. This is comparable to the rest of the industry: ZNTL outperforms 46.93% of its industry peers.
ZNTL has a Return On Equity (-66.82%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -52.96%
ROE -66.82%
ROIC N/A
ROA(3y)-43.93%
ROA(5y)-43.24%
ROE(3y)-55.01%
ROE(5y)-55.46%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ZNTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

ZNTL has more shares outstanding than it did 1 year ago.
ZNTL has more shares outstanding than it did 5 years ago.
ZNTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

There is no outstanding debt for ZNTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ZNTL has a Current Ratio of 7.16. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
ZNTL has a better Current ratio (7.16) than 69.11% of its industry peers.
ZNTL has a Quick Ratio of 7.16. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ZNTL (7.16) is better than 69.11% of its industry peers.
Industry RankSector Rank
Current Ratio 7.16
Quick Ratio 7.16

More info and screens

1

3. Growth

3.1 Past

ZNTL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.43%.
EPS 1Y (TTM)-2.43%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

ZNTL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.52% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.46%
EPS Next 2Y8.21%
EPS Next 3Y9.37%
EPS Next 5Y13.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZNTL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZNTL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.21%
EPS Next 3Y9.37%

More info and screens

0

5. Dividend

5.1 Amount

ZNTL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (5/3/2024, 8:26:37 PM)

After market: 11.71 0 (0%)

11.71

+0.6 (+5.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap830.94M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.96%
ROE -66.82%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 7.16
Quick Ratio 7.16
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-2.43%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y19.46%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y